Eysuvis FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 19, 2021.
FDA Approved: Yes (First approved October 26, 2020)
Brand name: Eysuvis
Generic name: loteprednol etabonate
Dosage form: Ophthalmic Suspension
Company: Kala Pharmaceuticals, Inc.
Treatment for: Dry Eye Disease
Eysuvis (loteprednol etabonate) is an ophthalmic corticosteroid formulation for the temporary relief of signs and symptoms of dry eye disease.
Development timeline for Eysuvis
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.